Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Head & Neck 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Melanoma 7Lung Neoplasms 7Small Cell Lung Carcinoma 6Carcinoma, Renal Cell 6Head and Neck Neoplasms 5Triple Negative Breast Neoplasms 4Advanced NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2NSCLC 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Skin Neoplasms 1Sarcopenia 1SCLC 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1NSCLC Stage IV Without EGFR/ALK Mutation 1Mesothelioma, Malignant 1Kidney Neoplasms 1Influenza, Human 1Hyperthermia 1

Interventions

pembrolizumab 9Nivolumab 4Carboplatin 4spartalizumab 2durvalumab 2Paclitaxel 2Immunohistochemistry 2Gemcitabine 2Cisplatin 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tremelimumab 1ribociclib 1regorafenib 1obinutuzumab 1naptumomab estafenatox 1liposomal doxorubicin 1enzalutamide 1atezolizumab 1aflibercept 1abiraterone 1SGN-LIV1A 1Ritonavir 1Remote Patient Monitoring 1Polymerase Chain Reaction 1Oxaliplatin 1NEO212 1Mass Spectrometry 1Lopinavir 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Immune Checkpoint Inhibitors × Thoracic × Clear all
NCT04721223 2024-09-19

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Jacobio Pharmaceuticals Co., Ltd.

Phase 1/2 Completed
12 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡